Androgen Receptor as a Licensing Factor for DNA Replication

  • Donald J. J. Vander Griend
  • John T. Isaacs


The Androgen Receptor (AR) is a steroid transcription factor, the activity of which is the primary focus of androgen ablation therapies for advanced prostate cancer. In prostate cancers, the AR acquires gain-of-function changes allowing it to drive prostate cancer cell survival and proliferation in a cell-autonomous manner. As part of this malignancy-associated gain-of-function, AR acquires a role in licensing for DNA replication in prostate cancer cells. In its role as a licensing factor, AR must be degraded during mitosis in order to allow re-licensing in the subsequent cell cycle. This conclusion is supported by the demonstration that acute enhanced expression of AR in prostate cancer cells results in its incomplete degradation in mitosis. This lack of mitotic AR degradation inhibits subsequent cell proliferation due to the inability to re-license all origins of replication needed for the next round of cell division. These data provide a unifying paradigm to clarify a number of unresolved observations in prostate cancer research. In addition, they provide a rationale for a new therapeutic approach for prostate cancer based upon stabilization of AR.


Androgen Receptor Prostate Cancer Cell Androgen Deprivation Therapy Androgen Receptor Protein License Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Arentson E, Faloon P, Seo J, Moon E, Studts JM, Fremont DH, and Choi K (2002). Oncogenic potential of the DNA replication licensing protein CDT1. Oncogene 21(8): 1150–1158PubMedCrossRefGoogle Scholar
  2. Arias EE and Walter JC (2007). Strength in numbers: preventing rereplication via multiple mechanisms in eukaryotic cells. Genes Dev 21(5): 497–518PubMedCrossRefGoogle Scholar
  3. Bai VU, Cifuentes E, Menon M, Barrack ER, and Reddy GP (2005). Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. J Cell Physiol 204(2): 381–387PubMedCrossRefGoogle Scholar
  4. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, and Loda M (2006). Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66(11): 5723–5728PubMedCrossRefGoogle Scholar
  5. Blow JJ and Tanaka TU (2005). The chromosome cycle: coordinating replication and segregation. Second in the cycles review series. EMBO Rep 6(11): 1028–1034PubMedCrossRefGoogle Scholar
  6. Chang CS, Kokontis J, and Liao ST (1988). Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240(4850): 324–326PubMedCrossRefGoogle Scholar
  7. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, and Sawyers CL (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1): 33–39PubMedCrossRefGoogle Scholar
  8. Cifuentes E, Croxen R, Menon M, Barrack ER, and Reddy GP (2003). Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase. J Cell Physiol 195(3): 337–345PubMedCrossRefGoogle Scholar
  9. Cunha GR, Cooke PS, and Kurita T (2004). Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 67(5): 417–434PubMedCrossRefGoogle Scholar
  10. Cvetic CA and Walter JC (2006). Getting a grip on licensing: mechanism of stable Mcm2–7 loading onto replication origins. Mol Cell 21(2): 143–144PubMedCrossRefGoogle Scholar
  11. De Marzo AM, Meeker AK, Epstein JI, and Coffey DS (1998). Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kipl in normal, hyperplastic, and neoplastic cells. Am J Pathol 153(3): 911–919PubMedCrossRefGoogle Scholar
  12. Dudderidge TJ, McCracken SR, Loddo M, Fanshawe TR, Kelly JD, Neal DE, Leung HY, Williams GH, and Stoeber K (2007). Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer 96(9): 1384–1393PubMedGoogle Scholar
  13. Gao J, Arnold JT, and Isaacs JT (2001). Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61(13): 5038–5044PubMedGoogle Scholar
  14. Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, Sanchez-Cespedes M, Mendez J, Antequera F, and Serrano M (2006). Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 440(7084): 702–706PubMedCrossRefGoogle Scholar
  15. Heinlein CA and Chang C (2004). Androgen receptor in prostate cancer. Endocr Rev 25(2): 276–308PubMedCrossRefGoogle Scholar
  16. Hook SS, Lin JJ, and Dutta A (2007). Mechanisms to control rereplication and implications for cancer. Curr Opin Cell Biol 19: 663–671PubMedCrossRefGoogle Scholar
  17. Huggins C, Stevens RE, and Hodges CV (1941). Studies on prostate cancer: II. the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209–223CrossRefGoogle Scholar
  18. Iizuka M, Sarmento OF, Sekiya T, Scrable H, Allis CD, and Smith MM (2007). Hbo1 Links p53-dependent stress signaling to DNA replication licensing. Mol Cell Biol 28(1): 140–153PubMedCrossRefGoogle Scholar
  19. Isaacs JT (1994). Role of androgens in prostatic cancer. Vitam Horm 49: 433–502PubMedCrossRefGoogle Scholar
  20. Isaacs JT and Isaacs WB (2004). Androgen receptor outwits prostate cancer drugs. Nat Med 10(1): 26–27PubMedCrossRefGoogle Scholar
  21. Karakaidos P, Taraviras S, Vassiliou LV, Zacharatos P, Kastrinakis NG, Kougiou D, Kouloukoussa M, Nishitani H, Papavassiliou AG, Lygerou Z, and Gorgoulis VG (2004). Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability – evidence of E2F-1 transcriptional control over hCdt1. Am J Pathol 165(4): 1351–1365PubMedCrossRefGoogle Scholar
  22. Kemppainen JA, Lane MV, Sar M, and Wilson EM (1992). Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267(2): 968–974PubMedGoogle Scholar
  23. Klokk TI, Kurys P, Elbi C, Nagaich AK, Hendarwanto A, Slagsvold T, Chang CY, Hager GL, and Saatcioglu F (2006). Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol 27(5): 1823–1843PubMedCrossRefGoogle Scholar
  24. Kokontis JM, Hay N, and Liao S (1998). Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12(7): 941–953PubMedCrossRefGoogle Scholar
  25. Krongrad A, Wilson CM, Wilson JD, Allman DR, and McPhaul MJ (1991). Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol 76(1–3): 79–88PubMedCrossRefGoogle Scholar
  26. Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, and Cunha GR (2001). Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8(2): 192–200PubMedCrossRefGoogle Scholar
  27. Kyprianou N and Isaacs JT (1988). Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122(2): 552–562PubMedCrossRefGoogle Scholar
  28. Langeler EG, van Uffelen CJ, Blankenstein MA, van Steenbrugge GJ, and Mulder E (1993). Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 23(3): 213–223PubMedCrossRefGoogle Scholar
  29. Lei M (2005). The MCM complex: its role in DNA replication and implications for cancer therapy. Curr Cancer Drug Targets 5(5): 365–380PubMedCrossRefGoogle Scholar
  30. Liontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B, Kotsinas A, Nahum O, Zoumpourlis V, Kouloukoussa M, Lygerou Z, Taraviras S, Kittas C, Bartkova J, Papavassiliou AG, Bartek J, Halazonetis TD, and Gorgoulis VG (2007). Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res 67(22): 10899–10909PubMedCrossRefGoogle Scholar
  31. Litvinov IV, De Marzo AM, and Isaacs JT (2003). Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88(7): 2972–2982PubMedCrossRefGoogle Scholar
  32. Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, and Isaacs JT (2006). Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A 103(41):15085–15090PubMedCrossRefGoogle Scholar
  33. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, and Wilson EM (1988). Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240(4850): 327–330PubMedCrossRefGoogle Scholar
  34. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, Weinberg V, Carroll PR, and Tlsty TD (2001). Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 7(9): 2712–2718PubMedGoogle Scholar
  35. Mottet N, Lucas C, Sene E, Avances C, Maubach L, and Wolff JM (2005). Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? Urol Int 75(3): 204–208PubMedCrossRefGoogle Scholar
  36. Padmanabhan V, Callas P, Philips G, Trainer TD, and Beatty BG (2004). DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol 57(10): 1057–1062PubMedCrossRefGoogle Scholar
  37. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, and Logothetis CJ (2004). Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11): 2108–2121PubMedCrossRefGoogle Scholar
  38. Quarmby VE, Yarbrough WG, Lubahn DB, French FS, and Wilson EM (1990). Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 4(1): 22–28PubMedCrossRefGoogle Scholar
  39. Rao PN and Johnson RT (1970). Mammalian cell fusion: studies on the regulation of DNA synthesis and mitosis. Nature 225(5228): 159–164PubMedCrossRefGoogle Scholar
  40. Singh P, Uzgare A, Litvinov I, Denmeade SR, and Isaacs JT (2006). Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 13(3): 653–666PubMedCrossRefGoogle Scholar
  41. Tabancay AP, Jr. and Forsburg SL (2006). Eukaryotic DNA replication in a chromatin context. Curr Top Dev Biol 76: 129–184PubMedCrossRefGoogle Scholar
  42. Takeda DY and Dutta A (2005). DNA replication and progression through S phase. Oncogene 24(17): 2827–2843PubMedCrossRefGoogle Scholar
  43. Takeda DY, Parvin JD, and Dutta A (2005). Degradation of Cdt1 during S phase is Skp2-independent and is required for efficient progression of mammalian cells through S phase. J Biol Chem 280(24): 23416–23423PubMedCrossRefGoogle Scholar
  44. Tatsumi Y, Sugimoto N, Yugawa T, Narisawa-Saito M, Kiyono T, and Fujita M (2006). Deregulation of Cdt1 induces chromosomal damage without rereplication and leads to chromosomal instability. J Cell Sci 119(Pt 15): 3128–3140PubMedCrossRefGoogle Scholar
  45. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, and Chinnaiyan AM (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748): 644–648PubMedCrossRefGoogle Scholar
  46. Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, Wagle N, Hwang DS, and Dutta A (2003). A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 11(4): 997–1008PubMedCrossRefGoogle Scholar
  47. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, and McConkey DJ (2003). Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2(9): 835–843PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.The Chemical Therapeutics Program and the Brady Urological InstituteThe Johns Hopkins University School of Medicine, Cancer Research BuildingOrleans streetUSA

Personalised recommendations